Application of Nivolumab and chemotherapy in the perioperative period of stage III non-small cell lung cancer<\/h4><\/div><\/div><\/div><\/div><\/div><\/div><\/div>![](\"https:\/\/www.funcbio.cn\/wp-content\/uploads\/2023\/11\/99999.png\" "\\"99999\\"")
<\/span><\/div>BACKGROUND \u80cc\u666f<\/div><\/h4><\/div>Approximately 20% of patients with non\u2013small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.<\/p>\n
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
METHODS \u7814\u7a76\u65b9\u6cd5<\/div><\/h4><\/div>In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety.<\/p>\n
\u5728\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u76842\u671f\u8bd5\u9a8c\u4e2d\uff0c\u6211\u4eec\u5c06\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u65b0\u8f85\u52a9\u6cbb\u7597Nivolumab\u52a0\u94c2\u7c7b\u5316\u7597\uff08\u5b9e\u9a8c\u7ec4\uff09\u6216\u5355\u72ec\u5316\u7597\uff08\u5bf9\u7167\u7ec4\uff09\uff0c\u7136\u540e\u8fdb\u884c\u624b\u672f\u3002\u5b9e\u9a8c\u7ec4\u4e2dR0\u5207\u9664\u7684\u60a3\u8005\u63a5\u53d7nivolumab\u7684\u8f85\u52a9\u6cbb\u75976\u4e2a\u6708\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff08\u5207\u9664\u7684\u80ba\u90e8\u548c\u6dcb\u5df4\u7ed3\u4e2d0%\u7684\u6d3b\u4f53\u80bf\u7624\uff09\u3002\u6b21\u8981\u7ec8\u70b9\u5305\u62ec24\u4e2a\u6708\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u548c\u603b\u751f\u5b58\u671f\u4ee5\u53ca\u5b89\u5168\u6027\u3002<\/p>\n<\/div><\/div><\/div>
RESULTS \u7ed3\u679c<\/div><\/h4><\/div>A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan\u2013 Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan\u2013Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%).<\/p>\n
\u5171\u670986\u540d\u60a3\u8005\u63a5\u53d7\u4e86\u968f\u673a\u5206\u7ec4\uff1b57\u4eba\u88ab\u5206\u914d\u5230\u5b9e\u9a8c\u7ec4\uff0c29\u4eba\u88ab\u5206\u914d\u5230\u5bf9\u7167\u7ec4\u3002\u5b9e\u9a8c\u7ec4\u670937%\u7684\u60a3\u8005\u51fa\u73b0\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff0c\u5bf9\u7167\u7ec4\u67097%\uff08\u76f8\u5bf9\u98ce\u9669\uff0c5.34\uff1b95%\u7f6e\u4fe1\u533a\u95f4[CI]\uff0c1.34\u81f321.23\uff1bP = 0.02\uff09\u3002\u5b9e\u9a8c\u7ec493%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff0c\u5bf9\u7167\u7ec469%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff08\u76f8\u5bf9\u98ce\u9669\uff0c1.35\uff1b95%CI\uff0c1.05\u81f31.74\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684Kaplan-Meier\u4f30\u8ba1\u503c\u4e3a67.2%\uff0c\u5bf9\u7167\u7ec4\u4e3a40.9%\uff08\u75be\u75c5\u8fdb\u5c55\u3001\u75be\u75c5\u590d\u53d1\u6216\u6b7b\u4ea1\u7684\u5371\u9669\u6bd4\u4e3a0.47\uff1b95%CI\uff0c0.25\u81f30.88\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u7684\u603b\u751f\u5b58\u7387Kaplan-Meier\u4f30\u8ba1\u4e3a85.0%\uff0c\u5bf9\u7167\u7ec4\u4e3a63.6%\uff08\u6b7b\u4ea1\u5371\u9669\u6bd4\u4e3a0.43\uff1b95%CI\uff0c0.19\u81f30.98\uff09\u3002\u5b9e\u9a8c\u7ec4\u670911\u540d\u60a3\u8005\u53d1\u751f3\u7ea7\u62164\u7ea7\u4e0d\u826f\u4e8b\u4ef6\uff0819%\uff1b\u4e00\u4e9b\u60a3\u8005\u540c\u65f6\u53d1\u751f\u4e24\u79cd\u7ea7\u522b\u7684\u4e8b\u4ef6\uff09\uff0c\u5bf9\u7167\u7ec4\u67093\u540d\u60a3\u8005\uff0810%\uff09\u3002<\/p>\n<\/div><\/div><\/div>
CONCLUSIONS \u7ed3\u8bba<\/div><\/h4><\/div>In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.<\/p>\n
\u5728\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u4e2d\uff0c\u56f4\u624b\u672f\u671f\u4f7f\u7528nivolumab\u52a0\u5316\u7597\u6cbb\u7597\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6bd4\u4f8b\u66f4\u9ad8\uff0c\u751f\u5b58\u671f\u66f4\u957f\u3002<\/p>\n
\u672c\u6587\u7ae0\u8f6c\u8f7d\u4e8e\uff1aSCI\u5929\u5929\u8bfb<\/p>\n
\u539f\u6587\u94fe\u63a5\uff1ahttps:\/\/mp.weixin.qq.com\/s\/PWTY3cPu6cveNEFNDqmBGg<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>","protected":false},"author":1,"featured_media":3568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[202],"tags":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-202"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":3,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":3582,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions\/3582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media\/3568"}],"wp:attachment":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/tags?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/span><\/div>BACKGROUND \u80cc\u666f<\/div><\/h4><\/div>Approximately 20% of patients with non\u2013small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.<\/p>\n
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
METHODS \u7814\u7a76\u65b9\u6cd5<\/div><\/h4><\/div>In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety.<\/p>\n
\u5728\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u76842\u671f\u8bd5\u9a8c\u4e2d\uff0c\u6211\u4eec\u5c06\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u65b0\u8f85\u52a9\u6cbb\u7597Nivolumab\u52a0\u94c2\u7c7b\u5316\u7597\uff08\u5b9e\u9a8c\u7ec4\uff09\u6216\u5355\u72ec\u5316\u7597\uff08\u5bf9\u7167\u7ec4\uff09\uff0c\u7136\u540e\u8fdb\u884c\u624b\u672f\u3002\u5b9e\u9a8c\u7ec4\u4e2dR0\u5207\u9664\u7684\u60a3\u8005\u63a5\u53d7nivolumab\u7684\u8f85\u52a9\u6cbb\u75976\u4e2a\u6708\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff08\u5207\u9664\u7684\u80ba\u90e8\u548c\u6dcb\u5df4\u7ed3\u4e2d0%\u7684\u6d3b\u4f53\u80bf\u7624\uff09\u3002\u6b21\u8981\u7ec8\u70b9\u5305\u62ec24\u4e2a\u6708\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u548c\u603b\u751f\u5b58\u671f\u4ee5\u53ca\u5b89\u5168\u6027\u3002<\/p>\n<\/div><\/div><\/div>
RESULTS \u7ed3\u679c<\/div><\/h4><\/div>A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan\u2013 Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan\u2013Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%).<\/p>\n
\u5171\u670986\u540d\u60a3\u8005\u63a5\u53d7\u4e86\u968f\u673a\u5206\u7ec4\uff1b57\u4eba\u88ab\u5206\u914d\u5230\u5b9e\u9a8c\u7ec4\uff0c29\u4eba\u88ab\u5206\u914d\u5230\u5bf9\u7167\u7ec4\u3002\u5b9e\u9a8c\u7ec4\u670937%\u7684\u60a3\u8005\u51fa\u73b0\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff0c\u5bf9\u7167\u7ec4\u67097%\uff08\u76f8\u5bf9\u98ce\u9669\uff0c5.34\uff1b95%\u7f6e\u4fe1\u533a\u95f4[CI]\uff0c1.34\u81f321.23\uff1bP = 0.02\uff09\u3002\u5b9e\u9a8c\u7ec493%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff0c\u5bf9\u7167\u7ec469%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff08\u76f8\u5bf9\u98ce\u9669\uff0c1.35\uff1b95%CI\uff0c1.05\u81f31.74\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684Kaplan-Meier\u4f30\u8ba1\u503c\u4e3a67.2%\uff0c\u5bf9\u7167\u7ec4\u4e3a40.9%\uff08\u75be\u75c5\u8fdb\u5c55\u3001\u75be\u75c5\u590d\u53d1\u6216\u6b7b\u4ea1\u7684\u5371\u9669\u6bd4\u4e3a0.47\uff1b95%CI\uff0c0.25\u81f30.88\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u7684\u603b\u751f\u5b58\u7387Kaplan-Meier\u4f30\u8ba1\u4e3a85.0%\uff0c\u5bf9\u7167\u7ec4\u4e3a63.6%\uff08\u6b7b\u4ea1\u5371\u9669\u6bd4\u4e3a0.43\uff1b95%CI\uff0c0.19\u81f30.98\uff09\u3002\u5b9e\u9a8c\u7ec4\u670911\u540d\u60a3\u8005\u53d1\u751f3\u7ea7\u62164\u7ea7\u4e0d\u826f\u4e8b\u4ef6\uff0819%\uff1b\u4e00\u4e9b\u60a3\u8005\u540c\u65f6\u53d1\u751f\u4e24\u79cd\u7ea7\u522b\u7684\u4e8b\u4ef6\uff09\uff0c\u5bf9\u7167\u7ec4\u67093\u540d\u60a3\u8005\uff0810%\uff09\u3002<\/p>\n<\/div><\/div><\/div>
CONCLUSIONS \u7ed3\u8bba<\/div><\/h4><\/div>In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.<\/p>\n
\u5728\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u4e2d\uff0c\u56f4\u624b\u672f\u671f\u4f7f\u7528nivolumab\u52a0\u5316\u7597\u6cbb\u7597\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6bd4\u4f8b\u66f4\u9ad8\uff0c\u751f\u5b58\u671f\u66f4\u957f\u3002<\/p>\n
\u672c\u6587\u7ae0\u8f6c\u8f7d\u4e8e\uff1aSCI\u5929\u5929\u8bfb<\/p>\n
\u539f\u6587\u94fe\u63a5\uff1ahttps:\/\/mp.weixin.qq.com\/s\/PWTY3cPu6cveNEFNDqmBGg<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>","protected":false},"author":1,"featured_media":3568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[202],"tags":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-202"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":3,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":3582,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions\/3582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media\/3568"}],"wp:attachment":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/tags?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Approximately 20% of patients with non\u2013small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.<\/p>\n
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
METHODS \u7814\u7a76\u65b9\u6cd5<\/div><\/h4><\/div>In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety.<\/p>\n
\u5728\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u76842\u671f\u8bd5\u9a8c\u4e2d\uff0c\u6211\u4eec\u5c06\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u65b0\u8f85\u52a9\u6cbb\u7597Nivolumab\u52a0\u94c2\u7c7b\u5316\u7597\uff08\u5b9e\u9a8c\u7ec4\uff09\u6216\u5355\u72ec\u5316\u7597\uff08\u5bf9\u7167\u7ec4\uff09\uff0c\u7136\u540e\u8fdb\u884c\u624b\u672f\u3002\u5b9e\u9a8c\u7ec4\u4e2dR0\u5207\u9664\u7684\u60a3\u8005\u63a5\u53d7nivolumab\u7684\u8f85\u52a9\u6cbb\u75976\u4e2a\u6708\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff08\u5207\u9664\u7684\u80ba\u90e8\u548c\u6dcb\u5df4\u7ed3\u4e2d0%\u7684\u6d3b\u4f53\u80bf\u7624\uff09\u3002\u6b21\u8981\u7ec8\u70b9\u5305\u62ec24\u4e2a\u6708\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u548c\u603b\u751f\u5b58\u671f\u4ee5\u53ca\u5b89\u5168\u6027\u3002<\/p>\n<\/div><\/div><\/div>
RESULTS \u7ed3\u679c<\/div><\/h4><\/div>A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan\u2013 Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan\u2013Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%).<\/p>\n
\u5171\u670986\u540d\u60a3\u8005\u63a5\u53d7\u4e86\u968f\u673a\u5206\u7ec4\uff1b57\u4eba\u88ab\u5206\u914d\u5230\u5b9e\u9a8c\u7ec4\uff0c29\u4eba\u88ab\u5206\u914d\u5230\u5bf9\u7167\u7ec4\u3002\u5b9e\u9a8c\u7ec4\u670937%\u7684\u60a3\u8005\u51fa\u73b0\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff0c\u5bf9\u7167\u7ec4\u67097%\uff08\u76f8\u5bf9\u98ce\u9669\uff0c5.34\uff1b95%\u7f6e\u4fe1\u533a\u95f4[CI]\uff0c1.34\u81f321.23\uff1bP = 0.02\uff09\u3002\u5b9e\u9a8c\u7ec493%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff0c\u5bf9\u7167\u7ec469%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff08\u76f8\u5bf9\u98ce\u9669\uff0c1.35\uff1b95%CI\uff0c1.05\u81f31.74\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684Kaplan-Meier\u4f30\u8ba1\u503c\u4e3a67.2%\uff0c\u5bf9\u7167\u7ec4\u4e3a40.9%\uff08\u75be\u75c5\u8fdb\u5c55\u3001\u75be\u75c5\u590d\u53d1\u6216\u6b7b\u4ea1\u7684\u5371\u9669\u6bd4\u4e3a0.47\uff1b95%CI\uff0c0.25\u81f30.88\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u7684\u603b\u751f\u5b58\u7387Kaplan-Meier\u4f30\u8ba1\u4e3a85.0%\uff0c\u5bf9\u7167\u7ec4\u4e3a63.6%\uff08\u6b7b\u4ea1\u5371\u9669\u6bd4\u4e3a0.43\uff1b95%CI\uff0c0.19\u81f30.98\uff09\u3002\u5b9e\u9a8c\u7ec4\u670911\u540d\u60a3\u8005\u53d1\u751f3\u7ea7\u62164\u7ea7\u4e0d\u826f\u4e8b\u4ef6\uff0819%\uff1b\u4e00\u4e9b\u60a3\u8005\u540c\u65f6\u53d1\u751f\u4e24\u79cd\u7ea7\u522b\u7684\u4e8b\u4ef6\uff09\uff0c\u5bf9\u7167\u7ec4\u67093\u540d\u60a3\u8005\uff0810%\uff09\u3002<\/p>\n<\/div><\/div><\/div>
CONCLUSIONS \u7ed3\u8bba<\/div><\/h4><\/div>In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.<\/p>\n
\u5728\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u4e2d\uff0c\u56f4\u624b\u672f\u671f\u4f7f\u7528nivolumab\u52a0\u5316\u7597\u6cbb\u7597\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6bd4\u4f8b\u66f4\u9ad8\uff0c\u751f\u5b58\u671f\u66f4\u957f\u3002<\/p>\n
\u672c\u6587\u7ae0\u8f6c\u8f7d\u4e8e\uff1aSCI\u5929\u5929\u8bfb<\/p>\n
\u539f\u6587\u94fe\u63a5\uff1ahttps:\/\/mp.weixin.qq.com\/s\/PWTY3cPu6cveNEFNDqmBGg<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>","protected":false},"author":1,"featured_media":3568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[202],"tags":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-202"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":3,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":3582,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions\/3582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media\/3568"}],"wp:attachment":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/tags?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety.<\/p>\n
\u5728\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u76842\u671f\u8bd5\u9a8c\u4e2d\uff0c\u6211\u4eec\u5c06\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u968f\u673a\u5206\u914d\u5230\u65b0\u8f85\u52a9\u6cbb\u7597Nivolumab\u52a0\u94c2\u7c7b\u5316\u7597\uff08\u5b9e\u9a8c\u7ec4\uff09\u6216\u5355\u72ec\u5316\u7597\uff08\u5bf9\u7167\u7ec4\uff09\uff0c\u7136\u540e\u8fdb\u884c\u624b\u672f\u3002\u5b9e\u9a8c\u7ec4\u4e2dR0\u5207\u9664\u7684\u60a3\u8005\u63a5\u53d7nivolumab\u7684\u8f85\u52a9\u6cbb\u75976\u4e2a\u6708\u3002\u4e3b\u8981\u7ec8\u70b9\u662f\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff08\u5207\u9664\u7684\u80ba\u90e8\u548c\u6dcb\u5df4\u7ed3\u4e2d0%\u7684\u6d3b\u4f53\u80bf\u7624\uff09\u3002\u6b21\u8981\u7ec8\u70b9\u5305\u62ec24\u4e2a\u6708\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u548c\u603b\u751f\u5b58\u671f\u4ee5\u53ca\u5b89\u5168\u6027\u3002<\/p>\n<\/div><\/div><\/div>
RESULTS \u7ed3\u679c<\/div><\/h4><\/div>A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan\u2013 Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan\u2013Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%).<\/p>\n
\u5171\u670986\u540d\u60a3\u8005\u63a5\u53d7\u4e86\u968f\u673a\u5206\u7ec4\uff1b57\u4eba\u88ab\u5206\u914d\u5230\u5b9e\u9a8c\u7ec4\uff0c29\u4eba\u88ab\u5206\u914d\u5230\u5bf9\u7167\u7ec4\u3002\u5b9e\u9a8c\u7ec4\u670937%\u7684\u60a3\u8005\u51fa\u73b0\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff0c\u5bf9\u7167\u7ec4\u67097%\uff08\u76f8\u5bf9\u98ce\u9669\uff0c5.34\uff1b95%\u7f6e\u4fe1\u533a\u95f4[CI]\uff0c1.34\u81f321.23\uff1bP = 0.02\uff09\u3002\u5b9e\u9a8c\u7ec493%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff0c\u5bf9\u7167\u7ec469%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff08\u76f8\u5bf9\u98ce\u9669\uff0c1.35\uff1b95%CI\uff0c1.05\u81f31.74\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684Kaplan-Meier\u4f30\u8ba1\u503c\u4e3a67.2%\uff0c\u5bf9\u7167\u7ec4\u4e3a40.9%\uff08\u75be\u75c5\u8fdb\u5c55\u3001\u75be\u75c5\u590d\u53d1\u6216\u6b7b\u4ea1\u7684\u5371\u9669\u6bd4\u4e3a0.47\uff1b95%CI\uff0c0.25\u81f30.88\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u7684\u603b\u751f\u5b58\u7387Kaplan-Meier\u4f30\u8ba1\u4e3a85.0%\uff0c\u5bf9\u7167\u7ec4\u4e3a63.6%\uff08\u6b7b\u4ea1\u5371\u9669\u6bd4\u4e3a0.43\uff1b95%CI\uff0c0.19\u81f30.98\uff09\u3002\u5b9e\u9a8c\u7ec4\u670911\u540d\u60a3\u8005\u53d1\u751f3\u7ea7\u62164\u7ea7\u4e0d\u826f\u4e8b\u4ef6\uff0819%\uff1b\u4e00\u4e9b\u60a3\u8005\u540c\u65f6\u53d1\u751f\u4e24\u79cd\u7ea7\u522b\u7684\u4e8b\u4ef6\uff09\uff0c\u5bf9\u7167\u7ec4\u67093\u540d\u60a3\u8005\uff0810%\uff09\u3002<\/p>\n<\/div><\/div><\/div>
CONCLUSIONS \u7ed3\u8bba<\/div><\/h4><\/div>In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.<\/p>\n
\u5728\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u4e2d\uff0c\u56f4\u624b\u672f\u671f\u4f7f\u7528nivolumab\u52a0\u5316\u7597\u6cbb\u7597\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6bd4\u4f8b\u66f4\u9ad8\uff0c\u751f\u5b58\u671f\u66f4\u957f\u3002<\/p>\n
\u672c\u6587\u7ae0\u8f6c\u8f7d\u4e8e\uff1aSCI\u5929\u5929\u8bfb<\/p>\n
\u539f\u6587\u94fe\u63a5\uff1ahttps:\/\/mp.weixin.qq.com\/s\/PWTY3cPu6cveNEFNDqmBGg<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>","protected":false},"author":1,"featured_media":3568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[202],"tags":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-202"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":3,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":3582,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions\/3582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media\/3568"}],"wp:attachment":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/tags?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan\u2013 Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan\u2013Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%).<\/p>\n
\u5171\u670986\u540d\u60a3\u8005\u63a5\u53d7\u4e86\u968f\u673a\u5206\u7ec4\uff1b57\u4eba\u88ab\u5206\u914d\u5230\u5b9e\u9a8c\u7ec4\uff0c29\u4eba\u88ab\u5206\u914d\u5230\u5bf9\u7167\u7ec4\u3002\u5b9e\u9a8c\u7ec4\u670937%\u7684\u60a3\u8005\u51fa\u73b0\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\uff0c\u5bf9\u7167\u7ec4\u67097%\uff08\u76f8\u5bf9\u98ce\u9669\uff0c5.34\uff1b95%\u7f6e\u4fe1\u533a\u95f4[CI]\uff0c1.34\u81f321.23\uff1bP = 0.02\uff09\u3002\u5b9e\u9a8c\u7ec493%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff0c\u5bf9\u7167\u7ec469%\u7684\u60a3\u8005\u8fdb\u884c\u4e86\u624b\u672f\uff08\u76f8\u5bf9\u98ce\u9669\uff0c1.35\uff1b95%CI\uff0c1.05\u81f31.74\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684Kaplan-Meier\u4f30\u8ba1\u503c\u4e3a67.2%\uff0c\u5bf9\u7167\u7ec4\u4e3a40.9%\uff08\u75be\u75c5\u8fdb\u5c55\u3001\u75be\u75c5\u590d\u53d1\u6216\u6b7b\u4ea1\u7684\u5371\u9669\u6bd4\u4e3a0.47\uff1b95%CI\uff0c0.25\u81f30.88\uff09\u3002\u5b9e\u9a8c\u7ec424\u4e2a\u6708\u7684\u603b\u751f\u5b58\u7387Kaplan-Meier\u4f30\u8ba1\u4e3a85.0%\uff0c\u5bf9\u7167\u7ec4\u4e3a63.6%\uff08\u6b7b\u4ea1\u5371\u9669\u6bd4\u4e3a0.43\uff1b95%CI\uff0c0.19\u81f30.98\uff09\u3002\u5b9e\u9a8c\u7ec4\u670911\u540d\u60a3\u8005\u53d1\u751f3\u7ea7\u62164\u7ea7\u4e0d\u826f\u4e8b\u4ef6\uff0819%\uff1b\u4e00\u4e9b\u60a3\u8005\u540c\u65f6\u53d1\u751f\u4e24\u79cd\u7ea7\u522b\u7684\u4e8b\u4ef6\uff09\uff0c\u5bf9\u7167\u7ec4\u67093\u540d\u60a3\u8005\uff0810%\uff09\u3002<\/p>\n<\/div><\/div><\/div>
CONCLUSIONS \u7ed3\u8bba<\/div><\/h4><\/div>In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.<\/p>\n
\u5728\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u4e2d\uff0c\u56f4\u624b\u672f\u671f\u4f7f\u7528nivolumab\u52a0\u5316\u7597\u6cbb\u7597\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6bd4\u4f8b\u66f4\u9ad8\uff0c\u751f\u5b58\u671f\u66f4\u957f\u3002<\/p>\n
\u672c\u6587\u7ae0\u8f6c\u8f7d\u4e8e\uff1aSCI\u5929\u5929\u8bfb<\/p>\n
\u539f\u6587\u94fe\u63a5\uff1ahttps:\/\/mp.weixin.qq.com\/s\/PWTY3cPu6cveNEFNDqmBGg<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>","protected":false},"author":1,"featured_media":3568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[202],"tags":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-202"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":3,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":3582,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions\/3582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media\/3568"}],"wp:attachment":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/tags?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.<\/p>\n
\u5728\u53ef\u5207\u9664\u7684IIIA\u6216IIIB\u671fNSCLC\u60a3\u8005\u4e2d\uff0c\u56f4\u624b\u672f\u671f\u4f7f\u7528nivolumab\u52a0\u5316\u7597\u6cbb\u7597\uff0c\u4e0e\u5355\u72ec\u5316\u7597\u76f8\u6bd4\uff0c\u75c5\u7406\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u6bd4\u4f8b\u66f4\u9ad8\uff0c\u751f\u5b58\u671f\u66f4\u957f\u3002<\/p>\n
\u672c\u6587\u7ae0\u8f6c\u8f7d\u4e8e\uff1aSCI\u5929\u5929\u8bfb<\/p>\n
\u539f\u6587\u94fe\u63a5\uff1ahttps:\/\/mp.weixin.qq.com\/s\/PWTY3cPu6cveNEFNDqmBGg<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/p>","protected":false},"excerpt":{"rendered":"
Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.<\/p>","protected":false},"author":1,"featured_media":3568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"content-type":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[202],"tags":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-202"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":3,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":3582,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/posts\/3576\/revisions\/3582"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media\/3568"}],"wp:attachment":[{"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.funcbio.cn\/en\/wp-json\/wp\/v2\/tags?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}